The Risk Of Dangerous Blood Clots And Strokes – Part 1 of 2
The Risk Of Dangerous Blood Clots And Strokes. A unknown anti-clotting drug to reduce the risk of dangerous blood clots and strokes in race with a type of heart rhythm disorder has been approved by the US Food and Drug Administration. Savaysa (edoxaban) is approved to treat people with atrial fibrillation that’s not caused by a heart valve problem. Atrial fibrillation – the most routine type of heart rhythm disorder – increases the risk of developing blood clots that can travel to the brain and cause a stroke.
Savaysa pills are also approved to nurse deep vein thrombosis and pulmonary embolism in people already treated with an injected or infused anti-clotting drug for five to 10 days, according to the FDA. Deep vein thrombosis is a blood clot that forms in a sagacious vein, usually in the lower leg or thigh. Pulmonary embolism is a potentially deadly condition that occurs when a deep vein blood clot breaks off and travels to an artery in the lungs, blocking blood flow.